These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia. Goa KL; Barradell LB; Plosker GL Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820 [TBL] [Abstract][Full Text] [Related]
3. Management of dyslipidemia in adults with diabetes. Haffner SM Diabetes Care; 1998 Jan; 21(1):160-78. PubMed ID: 9538988 [TBL] [Abstract][Full Text] [Related]
4. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Nesto RW Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526 [TBL] [Abstract][Full Text] [Related]
6. Diabetic dyslipidaemia: insights for optimizing patient management. Vergès B Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197 [TBL] [Abstract][Full Text] [Related]
7. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Woodman RJ; Chew GT; Watts GF Drugs; 2005; 65(1):31-74. PubMed ID: 15610050 [TBL] [Abstract][Full Text] [Related]
8. Management of hypercholesterolaemia in the patient with diabetes. Packard C; Olsson AG Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606 [TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil. A reappraisal of its pharmacological properties and place in the management of dyslipidaemia. Spencer CM; Barradell LB Drugs; 1996 Jun; 51(6):982-1018. PubMed ID: 8736620 [TBL] [Abstract][Full Text] [Related]
10. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy. Oki JC Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166 [TBL] [Abstract][Full Text] [Related]
11. Dyslipidemia, morbidity, and mortality in non-insulin-dependent diabetes mellitus. Lipoproteins and coronary heart disease in non-insulin-dependent diabetes mellitus. Laakso M J Diabetes Complications; 1997; 11(2):137-41. PubMed ID: 9101400 [TBL] [Abstract][Full Text] [Related]
13. Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Després JP; Lemieux I; Robins SJ Drugs; 2004; 64(19):2177-98. PubMed ID: 15456334 [TBL] [Abstract][Full Text] [Related]
14. Current, new and future treatments in dyslipidaemia and atherosclerosis. Chong PH; Bachenheimer BS Drugs; 2000 Jul; 60(1):55-93. PubMed ID: 10929930 [TBL] [Abstract][Full Text] [Related]
15. The current management of diabetic dyslipidaemia. Betteridge DJ Acta Diabetol; 2001; 38 Suppl 1():S15-9. PubMed ID: 11829449 [TBL] [Abstract][Full Text] [Related]
16. [Epidemiology of cardio-vascular complications of diabetes]. Grimaldi A; Heurtier A Diabetes Metab; 1999 Jun; 25 Suppl 3():12-20. PubMed ID: 10421988 [TBL] [Abstract][Full Text] [Related]
17. Pharmacologic treatment of type 2 diabetic dyslipidemia. Moon YS; Kashyap ML Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439 [TBL] [Abstract][Full Text] [Related]